<DOC>
	<DOC>NCT00205465</DOC>
	<brief_summary>To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.</brief_summary>
	<brief_title>Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Diagnosed with chronic plaque psoriasis for at least 6 months Prior systemic therapy Current or prior history of illness precluding use of immunomodulatory therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>